Sagimet Biosciences (STU:0O2) EV-to-Revenue : (As of Jun. 01, 2025)

View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sagimet Biosciences's enterprise value is €-26.58 Mil. Sagimet Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00 Mil. Therefore, Sagimet Biosciences's EV-to-Revenue for today is .

The historical rank and industry rank for Sagimet Biosciences's EV-to-Revenue or its related term are showing as below:

During the past 6 years, the highest EV-to-Revenue of Sagimet Biosciences was 74.73. The lowest was -49.92. And the median was -17.85.

STU:0O2's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.44
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-01), Sagimet Biosciences's stock price is €3.04. Sagimet Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00. Therefore, Sagimet Biosciences's PS Ratio for today is .

Sagimet Biosciences EV-to-Revenue Historical Data

The historical data trend for Sagimet Biosciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences EV-to-Revenue Chart

Sagimet Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-Revenue

Get a 7-Day Free Trial

14.63

Sagimet Biosciences Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-Revenue	Get a 7-Day Free Trial													-10.35	-28.54	-	-	-

Competitive Comparison of Sagimet Biosciences's EV-to-Revenue

For the Biotechnology subindustry, Sagimet Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sagimet Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

Sagimet Biosciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Sagimet Biosciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	-26.577	/	0
	=

Sagimet Biosciences's current Enterprise Value is €-26.58 Mil.
Sagimet Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Sagimet Biosciences (STU:0O2) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Sagimet Biosciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	3.04	/	0
	=

Sagimet Biosciences's share price for today is €3.04.
Sagimet Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

Sagimet Biosciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sagimet Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (STU:0O2) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

SGMT:USA 0O2:Germany

Address

155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402

Website

https://www.sagimet.com

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Sagimet Biosciences Headlines

No Headlines